All posts by PIER MARIA FORNASARI

PIER MARIA FORNASARI
2023-01-03

Transcriptional reprogramming from innate immune functions to a pro-thrombotic signature by monocytes in moderate-severe COVID-19

A study by Imperial College London, in the United Kingdom, shows an irregular activity of monocytes with a prothrombotic effect Among the complications most attributed to Covid-19 is thrombosis. The formation of blood clots in the veins or arteries in the weeks following the coronavirus infection , impairing blood circulation, was one of the symptoms seen frequently among patients around

Read More

No Comments InCovid-19
PIER MARIA FORNASARI
2023-01-03

In Shanghai, up to 70% 25 million population may have been infected with COVID-19

A senior doctor at one of Shanghai’s top hospitals says 70 per cent of the megacity’s population may have already been infected with COVID-19 during China’s huge surge in cases, state media are reporting. Key points: The steep rise in infections came after years of hardline restrictions were abruptly loosened last month, with little warning or

Read More

No Comments InCovid-19
PIER MARIA FORNASARI
2023-01-03

NIH clinical trial leads to atezolizumab approval for advanced alveolar soft part sarcoma

A clinical trial led by the National Cancer Institute (NCI), part of the National Institutes of Health, has resulted in the first approval of a treatment for advanced alveolar soft part sarcoma (ASPS). The immunotherapy drug atezolizumab (Tecentriq) was recently approved by the U.S. Food and Drug Administration (FDA)(link is external) for the treatment of adults and

Read More

No Comments InRARE DISEASES
PIER MARIA FORNASARI
2022-12-31

Coadministration of CD19- and CD22-Directed Chimeric Antigen Receptor T-Cell Therapy in Childhood B-Cell Acute Lymphoblastic Leukemia: A Single-Arm, Multicenter, Phase II Trial with a 99% response rate

An innovative immunotherapy combination has shown a stunning 99% response rate in children with relapsed leukemia. The phase 2 trial, run jointly between researchers at St. Jude Children’s Research Hospital in Memphis and Shanghai Children’s Hospital in China tested the therapy in 225 children who had relapsed after conventional treatment. The work published in the Journal

Read More

No Comments InCAR-T
PIER MARIA FORNASARI
2022-12-30

China’s COVID-19 wave forecast to have two peaks where cases could reach 4.2 million a day: ew modelling by Airfinity examining data from China’s regional provinces

China is predicted to see two peaks in cases as COVID-19 spreads throughout the country, the first peak in mid-January and the second in early March.  New modelling by Airfinity has examined data from China’s regional provinces. The current outbreak is growing more rapidly in some regions than in others. Cases are currently rising much

Read More

No Comments InCovid-19
PIER MARIA FORNASARI
2022-12-29

Two synthetic biology experiments offer hope for future cancer treatments with CAR-T cells

New immunotherapies can allow healing cells to be activated or deactivated according to the stage of the disease, while more accurately targeting tumors While CAR T therapy represents one of the most impressive innovations in cancer care, the treatment can cause autoimmune-like side effects. Many have contended with the dilemma of maximizing the therapy’s benefits

Read More

No Comments InCAR-T
PIER MARIA FORNASARI
2022-12-29

Pfizer Announces Positive Top-Line Results from Phase 3 Study of Hemophilia B Gene Therapy Candidate

 Pfizer announced positive top-line results from the Phase 3 BENEGENE-2 study (NCT03861273) evaluating fidanacogene elaparvovec, an investigational gene therapy, for the treatment of adult males with moderately severe to severe hemophilia B. The BENEGENE-2 study met its primary endpoint of non-inferiority and superiority in the annualized bleeding rate (ABR) of total bleeds post-fidanacogene elaparvovec infusion

Read More

No Comments InGENE THERAPY RARE DISEASES
PIER MARIA FORNASARI
2022-12-28

Researchers of Tel Aviv University use Smartwatches to Measure Safety of COVID Vaccine

Tel Aviv University researchers monitored the physiological data of close to 5,000 Israelis over two years In a first-of-its-kind study, researchers at Tel Aviv University equipped close to 5,000 Israelis with smartwatches and monitored their physiological parameters over two years. Of those monitored, 2,038 received the booster dose of the coronavirus vaccine, allowing the researchers

Read More

No Comments InUncategorized
PIER MARIA FORNASARI
2022-12-28

Mapping the hurdles for the clinical applications of ATMPs and Clinical trials of combined ATMPs: two forthcoming single-stage Horizon Europe framework programs

1) Mapping the hurdles for the clinical applications of Advanced Therapy Medicinal Products (ATMPs) Deadline model single-stage Planned opening date 12 January 2023 Deadline date 13 April 2023 17:00:00 Brussels time ExpectedOutcome: This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination 6 “Maintaining an innovative,

Read More

No Comments InUncategorized